Compile Data Set for Download or QSAR
maximum 50k data
Found 34 Enz. Inhib. hit(s) with all data for entry = 50014727
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146577(CHEMBL102311 | spirobenzoxazines analogues)
Affinity DataIC50:  0.200nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146578(CHEMBL103406 | spirobenzoxazines analogues)
Affinity DataIC50:  8nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146572(CHEMBL100402 | spirobenzoxazines analogues)
Affinity DataIC50:  10nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146566(CHEMBL440147 | spirobenzoxazines analogues)
Affinity DataIC50:  10nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146565(CHEMBL101157 | spirobenzoxazines analogues)
Affinity DataIC50:  10nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146562(CHEMBL100893 | spirobenzoxazines analogues)
Affinity DataIC50:  12nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146571(CHEMBL101187 | spirobenzoxazines analogues)
Affinity DataIC50:  15nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146576(CHEMBL316958 | spirobenzoxazines analogues)
Affinity DataIC50:  16nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146568(CHEMBL101935 | spirobenzoxazines analogues)
Affinity DataIC50:  20nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146573(CHEMBL101678 | spirobenzoxazines analogues)
Affinity DataIC50:  26nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146573(CHEMBL101678 | spirobenzoxazines analogues)
Affinity DataIC50:  29nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146577(CHEMBL102311 | spirobenzoxazines analogues)
Affinity DataIC50:  30nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146569(CHEMBL430676 | spirobenzoxazines analogues)
Affinity DataIC50:  41nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146570(CHEMBL100447 | spirobenzoxazines analogues)
Affinity DataIC50:  46nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146563(CHEMBL316849 | spirobenzoxazines analogues)
Affinity DataIC50:  50nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146578(CHEMBL103406 | spirobenzoxazines analogues)
Affinity DataIC50:  67nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146566(CHEMBL440147 | spirobenzoxazines analogues)
Affinity DataIC50:  70nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146567(CHEMBL320462 | spirobenzoxazines analogues)
Affinity DataIC50:  74nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146575(CHEMBL317919 | spirobenzoxazines analogues)
Affinity DataIC50:  140nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146570(CHEMBL100447 | spirobenzoxazines analogues)
Affinity DataIC50:  159nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146562(CHEMBL100893 | spirobenzoxazines analogues)
Affinity DataIC50:  180nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146576(CHEMBL316958 | spirobenzoxazines analogues)
Affinity DataIC50:  274nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146563(CHEMBL316849 | spirobenzoxazines analogues)
Affinity DataIC50:  380nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146568(CHEMBL101935 | spirobenzoxazines analogues)
Affinity DataIC50:  390nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146565(CHEMBL101157 | spirobenzoxazines analogues)
Affinity DataIC50:  550nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146574(CHEMBL103196 | spirobenzoxazines analogues)
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146571(CHEMBL101187 | spirobenzoxazines analogues)
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V1a receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146564(CHEMBL100069 | spirobenzoxazines analogues)
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146569(CHEMBL430676 | spirobenzoxazines analogues)
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146575(CHEMBL317919 | spirobenzoxazines analogues)
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146567(CHEMBL320462 | spirobenzoxazines analogues)
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146574(CHEMBL103196 | spirobenzoxazines analogues)
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146572(CHEMBL100402 | spirobenzoxazines analogues)
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVasopressin V2 receptor(Homo sapiens (Human))
Johnson And Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50146564(CHEMBL100069 | spirobenzoxazines analogues)
Affinity DataIC50: >1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]-AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed